Thirty years since the first report of the disease we now know as AIDS, scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, continue advancing toward our goal of a vaccine to prevent HIV infection. I am optimistic that we will succeed.

Related posts:

  1. NIH Scientists Advance Universal Flu Vaccine A universal influenza vaccine — so-called because it could potentially provide protection from all flu strains for decades — may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health....
  2. Priming with DNA vaccine makes avian flu vaccine work better The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), […]...
  3. MedicareCard.com – Statement of Anthony S. Fauci, M.D., and Daniel Rotrosen, M.D. National Institute of Allergy and Infectious Diseases, National Institutes of Health, on Food Allergy Awareness Week 2010 The National Institute of Allergy and Infectious Diseases (NIAID), the lead institute at the National Institutes of Health for food allergy research, is pleased to commemorate Food Allergy Awareness Week from May 9–15, 2010. First established in 1997 by the Food Allergy and Anaphylaxis Network (FAAN), a patient and family advocacy organization, this week is […]...
  4. Led Team Maps Route for Eliciting HIV Neutralizing Antibodies Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according to a study appearing in Science Express this week. The discoveries were made by a team led by the Vaccine Research Center (VRC) at the National Institute […]...
  5. H1NI? Higher Dose of Seasonal Flu Vaccine Provides Extra Protection Higher Dose of Seasonal Flu Vaccine Provides Extra Protection ...
  6. Medicare Card, NIH Funds 10 International Centers of Excellence for Malaria Research In an effort to accelerate the control of malaria and help eliminate it worldwide, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced approximately $14 million in first-year funding to establish 10 new malaria research centers around the world....
  7. Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners Men and women infected with HIV reduced the risk of transmitting the virus to their sexual partners by taking oral antiretroviral medicines when their immune systems were relatively healthy, according to findings from a large-scale clinical study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health....
  8. Medicare NIH funds four clinical trials to fight antimicrobial resistance The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new contracts for large-scale clinical trials that address the problem of antimicrobial resistance. Over the next five to six years, these new clinical trials will evaluate treatment alternatives for diseases for which antibiotics are prescribed most […]...
  9. Vaccinating Children against Flu Helps Protect Wider Community Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well. The study was conducted to determine if immunized children could act as a barrier to limit the spread of influenza to the wider, unvaccinated community, a concept known as herd immunity....
  10. NIH-sponsored research yields promising malaria drug candidate A chemical that rid mice of malaria-causing parasites after a single oral dose may eventually become a new malaria drug if further tests in animals and people uphold the promise of early findings. The compound, NITD609, was developed by an international team of researchers including Elizabeth A. Winzeler, Ph.D., a grantee of the National Institute […]...
  11. Study Examines Best Time for Healthy HIV-infected People to Begin Antiretrovirals A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on their level of CD4+ T-cells. An HIV-infected individual’s level of CD4+ T-cells–commonly referred to as their CD4 count–is a key measure of […]...
  12. Unprecedented effort to seek, test, and treat inmates with HIV Twelve scientific teams in more than a dozen states will receive National Institutes of Health grants to study effective ways to prevent and treat HIV/AIDS among people in the criminal justice system. The grants, announced today, will be awarded primarily by the National Institute on Drug Abuse (NIDA), with additional support from the National Institute […]...
  13. Genetically modified fungi kill malaria-causing parasites in mosquitoes Genetically modified fungi kill malaria-causing parasites in mosquitoes...
  14. Medicare Medical Care, Rapid Development of Drug-Resistant, 2009 H1N1 Influenza Reported in Two Cases Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Doctors who treat prolonged influenza infection should be aware that even a short course of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment strategies for their patients who have impaired immune function....
  15. NIH-Funded Study Finds Early HAART during TB Treatment Boosts Survival Rate in People Co-Infected with HIV and TB A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting eight weeks, as has been standard. This finding by scientists co-funded by the National Institute […]...